Biote

Biote Debt/Market Cap

The Debt to Market Capitalization Ratio of Biote (BTMD) as of Nov 3, 2026 is 113.02 %. In the previous year, Debt to Market Capitalization Ratio was 113.98 % — a change of -0.85% (lower).

Debt/Market Cap

113.02 %

YoY

-0.85%

Last updated:

Debt to Market Capitalization Ratio of Biote is 2025 113.02 % . Debt to Market Capitalization Ratio of Biote was 2024 113.98 % . It decreases by -0.85% lower compared to the previous year.

The Biote Debt/Market Cap history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt/Market Cap
Date
Debt/Market Cap
Jan 1, 2019
48.46 USD
Jan 1, 2020
43.55 USD
Jan 1, 2021
38.39 USD
Jan 1, 2022
123.82 USD
Jan 1, 2023
118.11 USD
Jan 1, 2024
113.98 USD
Jan 1, 2025
113.02 USD
The Biote Debt/Market Cap history
YEARDebt/Market CapYoY
113.02 %-0.85%
113.98 %-3.49%
118.11 %-4.61%
123.82 %+222.53%
38.39 %-11.85%
43.55 %-10.14%
48.46 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Biote Stock analysis

What does Biote do? biote Corp. generates revenue through its Biote Method platform, which offers certified practitioners comprehensive tools for hormone optimization. The platform includes education, training, certification, practice management software, inventory management software, and marketing support. Biote also sells a branded line of dietary supplements directly to practitioners and patients. The company's primary customers are Biote-certified practitioners who use the platform to build and manage hormone optimization programs, while the dietary supplements target patients seeking complementary wellness solutions. The Biote Method's proprietary clinical decision support (CDS) system helps physicians personalize patient dosing, enhancing the value proposition for practitioners. By providing end-to-end solutions—from certification to software tools—biote Corp. creates recurring revenue streams through ongoing platform usage and product sales. The company's focus on hormone replacement therapy (HRT) products and practitioner support positions it within the specialized healthcare market segment for bio-identical hormone therapy. biote Corp. differentiates itself through its woman-led structure and comprehensive approach to hormone optimization. The firm's revenue model relies on both service-based offerings for practitioners and direct sales of branded supplements. This dual approach ensures consistent income from certified practitioners who depend on the platform for practice management and from patients purchasing the supplement line as part of their wellness regimen. Biote is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Biote stock

Debt to Market Capitalization Ratio of Biote is 113.02 % in 2025.

Debt to Market Capitalization Ratio of Biote changed from 113.98 % to 113.02 %, representing a -0.85% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Debt to Market Capitalization Ratio Biote since 2006 – with annual values, charts, and detailed analysis.

Debt/Market Cap compares total debt to the market value of equity. It provides a market-based view of financial leverage.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Debt to Market Capitalization Ratio's Biote with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Biote

All Key Metrics — Biote